Steve Elms - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Steve Elms is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $253K. Lifetime open-market sales: $8.83M. Historical track record: 1/5 stars across 3 tracked purchases.
Profile
Steve Elms is a corporate insider at ADMA BIOLOGICS, INC. (ADMA). SEC records also connect Elms to Marker Therapeutics, Inc. (MRKR) and Elevation Oncology, Inc. (ELEV). Elms has reported 8 insider filings with the SEC since 2024. The most recent filing was in March 2026.
| Role | Insider |
|---|---|
| Notability | 26/100 |
Board memberships
- ADMA BIOLOGICS, INC.
- Marker Therapeutics, Inc.
- Elevation Oncology, Inc.
Reported roles
- Director
Awards & honors
- Director at multiple biotech companies
- Experience in immuno-oncology
- Involvement in clinical-stage product development
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 0% |
| 90-day win rate | 0% |
| Avg 5-day return | +0.10% |
| Avg 30-day return | -39.14% |
| Avg 90-day return | -53.76% |
| Best 30-day return | -36.84% |
Trading Pattern
InsiderAlpha's records for Steve Elms go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. The typical open-market purchase is $84K (3 buys totaling $253K). The largest single buy on record is $110K of ADMA in 2026. Sales side: 3 recorded sales totaling $8.83M, so the filing history runs sell-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Steve Elms has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Insider at ADMA BIOLOGICS, INC. (ADMA) - 4 filings, 2024 to 2026
- Director at Marker Therapeutics, Inc. (MRKR) - 2 filings, 2024 to 2025
- Insider at Elevation Oncology, Inc. (ELEV) - 2 filings, 2025
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-09 | ADMA | ADMA BIOLOGICS, INC. | P - Open-market purchase | 7.0K | $15.39 | $108K |
| 2026-03-09 | ADMA | ADMA BIOLOGICS, INC. | P - Open-market purchase | 7.0K | $15.67 | $110K |
| 2026-02-12 | ADMA | ADMA BIOLOGICS, INC. | A - Grant or award | 10.7K | $0.00 | |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | S - Open-market sale | 194.7K | $20.24 | $3.94M |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | S - Open-market sale | 137.9K | $20.82 | $2.87M |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 37.5K | $5.40 | $203K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 51.6K | $3.35 | $173K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 53.2K | $1.67 | $89K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 55.0K | $2.35 | $129K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 15.0K | $2.92 | $44K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 30.0K | $3.89 | $117K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 17.5K | $4.91 | $86K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 53.8K | $3.66 | $197K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 10.0K | $5.00 | $50K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 9.0K | $5.96 | $54K |
| 2025-06-16 | ADMA | ADMA BIOLOGICS, INC. | S - Open-market sale | 92.9K | $21.69 | $2.02M |
| 2024-12-26 | MRKR | Marker Therapeutics, Inc. | P - Open-market purchase | 11.1K | $3.20 | $35K |
| 2024-12-02 | ADMA | ADMA BIOLOGICS, INC. | M - Option exercise | 9.0K | $10.80 | $97K |
Most Active Insiders Right Now
Steve Elms has no recent co-filers at the same companies, so here are the insiders with the largest open-market activity across the market in the last 90 days.
- MetLife Investment Management, LLC - $1600000.00B of FINS open-market activity in the last 90 days
- Magnetar Financial LLC - $16357.48B of CRWV open-market activity in the last 90 days
- Marianne Okland - $18.46B of STNG open-market activity in the last 90 days
- VisionWave Holdings, Inc. - $14.13B of SVRE open-market activity in the last 90 days
- Vanessa Allen Sutherland - $7.44B of PSX open-market activity in the last 90 days
- AI Alpine (Luxembourg) S.a.r.l. - $2.69B of INIO open-market activity in the last 90 days
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- Joseph Stilwell
- William P. Stiritz
- SUMITOMO MITSUI FINANCIAL GROUP, INC.
- Suva
- SUVRETTA CAPITAL MANAGEMENT, LLC
- Donald William Swanson
- Synchron
- Kevin Tang
Frequently Asked Questions
Who is Steve Elms?
Steve Elms is a corporate insider at ADMA BIOLOGICS, INC. (ADMA). SEC records also connect Elms to Marker Therapeutics, Inc. (MRKR) and Elevation Oncology, Inc. (ELEV). Elms has reported 8 insider filings with the SEC since 2024. The most recent filing was in March 2026.…
Has Steve Elms been buying or selling stock?
Recorded transactions: 3 open-market purchases ($253K) and 3 open-market sales ($8.83M) across all tracked filings.
How accurate is Steve Elms's historical track record?
Across 3 tracked purchases, Steve Elms averaged -39.1% avg 30-day return with a 0% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
Where can I see all of Steve Elms's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Steve Elms profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.